As PacBio Orders Decline in Q1, Company Bets on Happy Customers for Future Sales | GenomeWeb

This article was originally published May 2.

Following a drop in orders for its PacBio RS instrument as a result of issues with the instrument's reliability and performance in customers' hands, Pacific Biosciences has recently been focusing on its installed base, a company representative said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.